Our venture studio model optimally aligns drug development opportunities with financing and experimental execution to increase success rates and shorten timelines. Foundery I LP, our investment arm, is overseen by our founding team of storied drug developers and provides our studio with access to financial capital. We have fully functioning labs to evaluate, validate, and prioritize drug target candidates and develop IND-enabling drug packages that can be out-licensed or used to spin-out companies (NewCos). Collectively, we aim to maximize the chance of new drug development opportunities achieving clinical proof-of-concept (POC) and minimize the time to obtain clinical POC data with the ultimate goal of bringing more groundbreaking therapies to patients.
Our laboratories employ a team of highly experienced, dedicated, and focused drug developers with expertise in leading programs, antibody engineering, protein science, immune systems biology, in vitro pharmacology, in vivo pharmacology, bioanalytics, and biomarkers. We utilize AI-enabled target validation and quick-kill experiments to efficiently de-risk therapeutic candidates and develop first-in-class therapies with improved chances of therapeutic and commercial success.
